臨床婦人科産科71巻10号

2017年10月発行

今月の臨床 最新！　婦人科がん薬物療法─化学療法薬から分子標的薬・免疫療法薬まで

最新の副作用対策

発熱性好中球減少症に対するG-CSFと抗菌薬の適正使用

著者： 温泉川真由¹²

所属機関： ¹がん研究会有明病院総合腫瘍科 ²がん研究会有明病院婦人科

ページ範囲：P.913 - P.918

文献概要

●発熱性好中球減少の定義は，①1回の腋窩温が37.5℃以上または口腔内温が38℃以上で，②好中球数1,000μL未満で500/μL未満に減少すると予測される場合である．

●発熱性好中球減少に際しては全身状態確認，必要な検査を施行後，速やかに（60分以内）広域抗菌薬を開始すべきである．

●発熱性好中球減少後の対応としては，抗がん剤の減量，G-CSFの2次予防としての使用，予防的抗菌薬投与がある．治療目的により使い分ける必要がある．

参考文献

1）Freifeld AG, et al : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis 52 : e56─93, 2011

2）日本臨床腫瘍学会（編） : 発熱性好中球減少症（FN）診療ガイドライン．南江堂，2012

3）Katsumata N, et al : Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomised controlled trial. Lancet 374 : 1331─1338, 2009

4）Burger RA, et al : Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 : 2473─2483, 2011

5）Tewari KS, et al : Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370 : 734─743, 2014

6）Horwich A, et al : Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer : a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15 : 1844─1852, 1997

7）Toussaint E, et al : Causes of fever in cancer patients（prospective study over 477 episodes）. Support Care Cancer 14 : 763─769, 2006

8）Cockerill FR, 3rd, et al : Optimal testing parameters for blood cultures. Clin Infect Dis 38 : 1724─1730, 2004

9）Blot F, et al : Diagnosis of catheter-related bacteraemia : a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 354 : 1071─1077, 1999

10）Pizzo PA : Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328 : 1323─1332, 1993

11）Sundararajan V, et al : Controversies in new antibiotic therapy for ambulatory patients. Support Care Cancer 5 : 358─364, 1997

12）Bodey GP : The treatment of febrile neutropenia : from the Dark Ages to the present. Support Care Cancer 5 : 351─357, 1997

13）Klastersky J, et al : Management of febrile neutropaenia : ESMO Clinical Practice Guidelines. Ann Oncol 27 : v111─v118, 2016

14）Flowers CR, et al : Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy : American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31 : 794─810, 2013

15）Klastersky J, et al : The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 : 3038─3051, 2000

16）Cullen M, et al : Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353 : 988─998, 2005

17）Smith TJ, et al : Recommendations for the Use of WBC Growth Factors : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33 : 3199─3212, 2015

18）Mhaskar R, et al : Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev : CD003039, 2014